LIV Emles at Home ETF

Samaritan Pharmaceuticals Inc. (AMEX:LIV): -- Clears Clogged Arteries -- Raises HDL -- Reduces CK Enzyme Marker: Suggesting It Improves, Hypercholesterolemia-Related Heart Suffering, Which Commonly Leads to Heart Attacks Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs, announced today, it has filed a new provisional U.S. patent application to support its original application, and add additional claims, for its cardiovascular drug SP-1000 for the prevention and treatment of cardiovascular disease. Samaritan's collaborating scientists, through animal studies, validated SP-1000's ability to reduce blood cholesterol in animals. In addition, researchers validated SP-1000's ability, to clear clogged arteries of atheroma; raise HDL, the good cholesterol; and reduce CK enzyme elevations, a marker for heart suffering in animals. Additionally, researchers have identified SP-1000 as having a new mechanism of action, i.e. it directly targets cholesterol in the blood and appears to be active at the lowest dose tested, which could suggest minimal side effects if tested in people. SP 1000 was discovered by researchers from Georgetown University and is exclusively licensed to Samaritan. SP-1000's effect in reducing circulating cholesterol levels was validated with two hypercholesterolemia animal studies, one with ApoE knockout mice and another with guinea pigs. Previously, on March 28, 2006 Samaritan announced that new preclinical data from animal studies showed SP-1000 reduces cholesterol. Upon further analysis of scientific data from these animal studies, Samaritan found new claims to protect with a new provisional U.S. patent application. Dr. Greeson, CEO of Samaritan stated, "Although we feel extremely positive, I need to express a cautionary optimism in that animal studies do not necessarily mean SP-1000 will work in people. It does validate our original thesis as to how we think this drug works. In addition, animal studies are enough to start looking to out-license SP-1000 to a major pharmaceutical and/or perform additional preclinical trials in preparation to file an IND with the FDA to investigate SP-1000 in people." Samaritan Pharmaceuticals: "We LIV....to Save Lives." Samaritan is a small-cap Biotech, driven to discover, develop and commercialize innovative therapeutics' for AIDS, Alzheimer's, Cancer and Heart disease patients. Look at www.samaritanpharma.com. Please register on Website so we can notify you of upcoming conference calls, news and events. Disclaimer The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 15, 2005. The company undertakes no duty to update forward-looking statements.